⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiaryHigh fills per patient
Risk indicators are statistical patterns, not allegations. Learn more
12,215
Total Claims
$2.7M
Drug Cost
575
Beneficiaries
$4,775
Cost/Patient
Risk Score Breakdown 7/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
High fills per patient+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+21%
Cost per patient vs peers
$4,775 vs $3,933 avg
-16%
Brand preference vs peers
42.7% vs 51.2% avg
Brand vs Generic
57% generic
Brand: 4,866 claims · $2.6M
Generic: 6,520 claims · $110K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 467 | $482K |
| Empagliflozin | 430 | $306K |
| Semaglutide | 299 | $291K |
| Empagliflozin/Metformin Hcl | 262 | $177K |
| Insulin Glargine,hum.Rec.Anlog | 402 | $148K |
| Somatropin | 44 | $134K |
| Semaglutide | 121 | $123K |
| Insulin Glargine/Lixisenatide | 96 | $90K |
| Insulin Lispro | 144 | $75K |
| Levothyroxine Sodium | 1,180 | $75K |
| Sitagliptin Phos/Metformin Hcl | 114 | $74K |
| Sitagliptin Phosphate | 91 | $67K |
| Dapagliflozin Propanediol | 99 | $61K |
| Empagliflozin/Metformin Hcl | 77 | $57K |
| Tirzepatide | 38 | $51K |
Prescribing Profile
Patient Profile
71
Avg Age
69%
Female
1.87
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About